您的位置: 首页 > 文字全文
2023年7月 第38卷 第7期11
目录

基于“荣泣卫除”理论探讨PI3K/AKT通路介导的炎症反应对冠心病的调控机制

Regulatory Mechanism of PI3K/AKT Pathway-Mediated Inflammatory Response on Coronary Heart Disease Based on the Theory of "Depletion of Nutritive Level and Exhaustion of Defensive Level"

来源期刊: 广州医药 | - 发布时间: 收稿时间:2026/6/5 15:24:32 阅读量:21
作者:
关键词:
冠心病;荣泣卫除;PI3K/Akt通路;炎症反应;中医药防治
Coronary heart disease; Depletion of nutritive level and exhaustion of defensive level; PI3K/Akt pathway; Inflammatory response; Traditional Chinese medicine prevention and treatment
DOI:
收稿时间:
 
修订日期:
 
接收日期:
 
引用总数:
0  
冠心病是临床高发的心血管疾病,其病理核心为动脉粥样硬化,而炎症反应异常激活是推动病变进展的关键驱动力。PI3K/Akt通路通过调控炎症反应等,在CHD进程中发挥双向调节作用。现代研究表明,该通路保护性激活不足可加剧血管内皮损伤与斑块不稳定性,而炎症反应的持续又可进一步抑制PI3K/Akt通路活性,形成恶性循环。当动脉粥样斑块破裂,AMI发生后炎症级联反应放大,该通路异常激活,诱发MIRI。“荣泣卫除”出自《黄帝内经》,指营气耗损(荣泣)、卫气失守(卫除),荣卫失和则气血运行不畅、脉络瘀阻。本团队结合该理论与现代研究,认为CHD中PI3K/Akt通路介导的异常炎症反应的病理机制,与“荣泣卫除”理论内涵存在对应关系。研究发现,通过调控PI3K/Akt通路活性,抑制炎症因子激活与炎症蛋白表达,可抑制CHD发生发展进程。故本文基于“荣泣卫除”理论,系统梳理了PI3K/Akt通路介导的炎症反应在CHD中的作用及与中医病机的内在关联,总结中医药防治的研究进展,为中西医结合防治CHD提供参考依据。
Coronary heart disease is a clinically prevalent cardiovascular disease, with atherosclerosis as its core pathology. Abnormal activation of the inflammatory response is a key driving force for disease progression. The PI3K/Akt pathway exerts bidirectional regulatory effects on the progression of CHD by modulating inflammatory responses, among other functions. Modern studies indicate that insufficient protective activation of this pathway can exacerbate vascular endothelial injury and plaque instability, while persistent inflammation further suppresses PI3K/Akt pathway activity, forming a vicious cycle. Following atherosclerotic plaque rupture and the onset of AMI, the inflammatory cascade is amplified, leading to aberrant activation of this pathway and triggering MIRI. The theory of "depletion of nutritive level and exhaustion of defensive level" originates from the?Yellow Emperor's Inner Classic, referring to the depletion of nutritive level (Rong Qi) and the exhaustion of defensive level (Wei Qi), resulting in disharmony between nutritive and defensive levels, which impedes the smooth flow of Qi and blood and causes stasis in the collaterals. By integrating this theory with modern research, our team proposes a correspondence between the pathological mechanism of abnormal PI3K/Akt pathway-mediated inflammatory response in CHD and the theoretical connotation of "depletion of nutritive level and exhaustion of defensive level". Studies have found that modulating PI3K/Akt pathway activity to inhibit the activation of inflammatory factors and expression of inflammatory proteins can suppress the occurrence and progression of CHD. Therefore, based on the theory of "depletion of nutritive level and exhaustion of defensive level", this paper systematically reviews the role of the PI3K/Akt pathway-mediated inflammatory response in CHD and its intrinsic relationship with traditional Chinese medicine pathogenesis, summarizes research progress in TCM prevention and treatment, and provides a reference for the integrated traditional Chinese and Western medicine management of CHD.
1、【1】Beverly JK, Budoff MJ. Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes. 2020 Feb;12(2):102-104. doi: 10.1111/1753-0407.12970. Epub 2019 Aug 14. PMID: 31411812. 【2】葛均波,王辰,王建安.内科学[M].北京:人民卫生出版社,2024. 【3】中国心血管健康与疾病报告2024概要[J].中国循环杂志,2025,40(06):521-559. 【4】Ajoolabady A, Pratico D, Lin L, Mantzoros CS, Bahijri S, Tuomilehto J, Ren J. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024 Nov 11;15(11):817. doi: 10.1038/s41419-024-07166-8. PMID: 39528464; PMCID: PMC11555284. 【5】Acosta-Martinez, M.; Cabail, M.Z. The PI3K/Akt Pathway in Meta-Inflammation. Int. J. Mol. Sci. 2022, 23, 15330. https://doi.org/10.3390/ijms232315330 【6】毛文君,张艳.基于“营卫理论”探讨桂枝汤类方治疗冠心病的机制及研究进展[J].山西中医药大学学报,2025,26(06):690-699.DOI:10.19763/j.cnki.2096-7403.2025.06.19. 【7】温亮,韩秀平,谢燚,等 .薤白皂苷对冠心病模型大鼠心肌细胞 凋亡及炎性因子、NF-κB表达的影响[J].中西医结合心脑血管病杂志,2022,20(13):2359-2364. 【8】Bilancio A, Rinaldi B, Oliviero MA, Donniacuo M, Monti MG, Boscaino A, Marino I, Friedman L, Rossi F, Vanhaesebroeck B, Migliaccio A. Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep. 2017 Sep 27;37(5):BSR20171112. doi: 10.1042/BSR20171112. PMID: 28851839; PMCID: PMC5617917. 【9】吴瑛滢,戴斌,韩旭,等.中医药通过磷脂酰肌醇3激酶-蛋白激酶B及核转录因子-кB通路干预动脉粥样硬化的研究综述[J].中医临床研究,2025,17(15):24-28. 【10】王莹.基于DNA羟甲基化和PI3K/AKT通路探讨冠心病血瘀证的发病机制及养心通脉方干预研究[D].湖南中医药大学,2025.DOI:10.27138/d.cnki.ghuzc.2025.000305. 【11】Zhu, Zhongsheng, Li, Jinyu, Tong, Rui, Zhang, Xiaorong, Yu, Bo, miR-149 Alleviates Ox-LDL-Induced Endothelial Cell Injury by Promoting Autophagy through Akt/mTOR Pathway, Cardiology Research and Practice, 2021, 9963258, 9 pages, 2021. https://doi.org/10.1155/2021/9963258. 【12】孙友俊.MicroRNA-31激活ROCK1介导的PI3K/AKT信号通路改善LPS诱导的内皮细胞炎症和通透性研究[D].安徽医科大学,2022.DOI:10.26921/d.cnki.ganyu.2022.001248. 【13】Chao Peng, Gui-jing Liu, Jian Li, Yan Chen, Xi-hai Zhu, Hao Yin, Hong-wen Li, Yu-hang Jiang, Xin-yu Yang, Yan Zhao, Xiao-jun Zhang,Evolocumab alleviates atherogenesis by inhibiting inflammation-mediated endothelial cell activation via the PI3K/AKT/NF-κB pathway,European Journal of Pharmacology,Volume 1020,2026,178777,ISSN 0014-2999,https://doi.org/10.1016/j.ejphar.2026.178777. 【14】Zhang M, Yue X, Zhao X, Lu Y, Liu H, Zhang Z, Ma H, Wang X, Xing H. Macrophage-specific deletion of Notch-1 induced M2 anti-inflammatory effect in atherosclerosis via activation of the PI3K-oxidative stress axis. Aging (Albany NY). 2023 Dec 26;15(24):15196-15212. doi: 10.18632/aging.205342. Epub 2023 Dec 26. PMID: 38149979; PMCID: PMC10781475. 【15】郑艳,马振,王南丁,等.基于PI3K/AKT/eNOS通路研究芪丹通脉片对ApoE-/-小鼠动脉粥样硬化易损斑块的影响[J].中医学报,2024,39(01):55-62.DOI:10.16368/j.issn.1674-8999.2024.01.011. 【16】Deng RM, Zhou J. The role of PI3K/AKT signaling pathway in myocardial ischemia-reperfusion injury. Int Immunopharmacol. 2023 Oct;123:110714. doi: 10.1016/j.intimp.2023.110714. Epub 2023 Jul 29. PMID: 37523969. 【17】Ming Yang, Dongming Lin, Liming He, Xinxin Shi, Yucheng Wang, Yong Jin, Shuwei Huang,Cinnamaldehyde mitigates acute myocardial infarction by regulating ferroptosis through the PI3K-AKT signaling pathway,International Immunopharmacology,Volume 50,2025,114262,ISSN 1567-5769,https://doi.org/10.1016/j.intimp.2025.114262. 【18】Ding J, Wang Y, Fang X. Glycitin Alleviates Myocardial Ischemia-reperfusion Injury By Suppressing Oxidative Stress and Apoptosis Through PI3K/Akt/NF-κB Pathway Modulation. Appl Biochem Biotechnol. 2026 Mar 28. doi: 10.1007/s12010-026-05660-7. Epub ahead of print. PMID: 41903050. 【19】Chang JH, Jin MM, Liu JT. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro. Biomed Pharmacother. 2020 Jul;127:110188. doi: 10.1016/j.biopha.2020.110188. Epub 2020 May 11. PMID: 32407987. 【20】Zheng B, Qi J, Yang Y, Li L, Liu Y, Han X, Qu W, Chu L. Mechanisms of cinnamic aldehyde against myocardial ischemia/hypoxia injury in vivo and in vitro: Involvement of regulating PI3K/AKT signaling pathway. Biomed Pharmacother. 2022 Mar;147:112674. doi: 10.1016/j.biopha.2022.112674. Epub 2022 Jan 29. PMID: 35093758. 【21】唐启为,徐惠娟,刘歆雅,等.六经辨证视域下代谢综合征合并冠心病的病机与动态辨治规律探讨[J/OL].中华中医药学刊,1-10[2026-04-10].https://link.cnki.net/urlid/21.1546.R.20251118.1100.002. 【22】刘培,俞赟丰,杨欣雨,等.基于“痰、瘀、毒”理论探讨冠心病炎症机制和中药干预策略[J].中国实验方剂学杂志,2023,29(12):185-191.DOI:10.13422/j.cnki.syfjx.202202123. 【23】杨雅倩,谢盈彧,王丽蓉,等.运用营卫气血理论辨治冠状动脉重度狭窄[J].中医杂志,2020,61(02):126-129.DOI:10.13288/j.11-2166/r.2020.02.009. 【24】Yang P, Zhou Y, Xia Q, Yao L, Chang X. Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia-Reoxygenation. Biol Pharm Bull. 2019 May 1;42(5):721-727. doi: 10.1248/bpb.b18-00854. Epub 2019 Mar 13. PMID: 30867343. 【25】顾静,荆爽,韩晓斐,等.黄芪甲苷对辐射诱导的大鼠H9C2心肌细胞凋亡及miR-134-5p/BDNF/PI3K信号通路的影响[J/OL].中药药理与临床,1-16[2026-03-29].https://doi.org/10.13412/j.cnki.zyyl.20250919.001. 【26】李友乾,尉希清,宋秉春,等.黄芪甲苷对大鼠颈总动脉内膜增殖、炎症反应及PI3K/Akt/mTOR信号通路的影响[J].中国病理生理杂志,2023,39(04):677-683. 【27】Qin GW, Lu P, Peng L, Jiang W. Ginsenoside Rb1 Inhibits Cardiomyocyte Autophagy via PI3K/Akt/mTOR Signaling Pathway and Reduces Myocardial Ischemia/Reperfusion Injury. Am J Chin Med. 2021;49(8):1913-1927. doi: 10.1142/S0192415X21500907. Epub 2021 Nov 13. PMID: 34775933. 【28】董嘉琪.生脉散调控应激颗粒-氧化应激-线粒体内质网互作改善热应激大鼠心肌损伤的研究[D].甘肃农业大学,2025.DOI:10.27025/d.cnki.ggsnu.2025.000032. 【29】Yang W, Lai Q, Zhang L, Zhang Y, Zhang Y, Yu B, Li F, Kou J. Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury. J Ethnopharmacol. 2021 Jan 10;264:113381. doi: 10.1016/j.jep.2020.113381. Epub 2020 Sep 15. PMID: 32946961. 【30】马露,杨雷,邓常清,等.基于PI3K/Akt通路研究内皮祖细胞来源外泌体协同丹参酮ⅡA对血管内皮细胞氧化损伤的保护作用[J].中国中药杂志,2023,48(23):6423-6433.DOI:10.19540/j.cnki.cjcmm.20230828.701. 【31】Su Q, Lv X, Ye Z. Ligustrazine Attenuates Myocardial Injury Induced by Coronary Microembolization in Rats by Activating the PI3K/Akt Pathway. Oxid Med Cell Longev. 2019 May 2;2019:6791457. doi: 10.1155/2019/6791457. PMID: 31191802; PMCID: PMC6525935. 【32】黄安岑,周颖,王韵烨,等.红花黄色素对大鼠脑缺血再灌注损伤炎症因子及PI3K/AKT 通路的影响[J/OL].成都医学院学报,1-9[2026-03-29].https://link.cnki.net/urlid/51.1705.r.20250224.0925.002. 【33】朱浩,胡丽娟,万婧.血府逐瘀合剂通过调控TLR4/PI3K/AKT/mTOR信号通路改善冠心病大鼠心肌损伤[J].广州中医药大学学报,2025,42(10):2539-2548.DOI:10.13359/j.cnki.gzxbtcm.2025.10.026. 【34】Zhai X, Chen X, Xiao X and Wu L (2025) Application of network pharmacology in traditional Chinese medicine for the treatment of cardiac diseases . Front. Pharmacol. 16:1703454. doi: 10.3389/fphar.2025.1703454 【35】林泉.西洋参丹参配伍调控PI3K/Akt/NF-κB通路稳定动脉粥样硬化易损斑块的作用机制研究[D].中国中医科学院,2021.DOI:10.27658/d.cnki.gzzyy.2021.000047. 【36】Gao J, Guo H, Li J, Zhan M, You Y, Xin G, Liu Z, Fan X, Gao Q, Liu J, Zhang Y, Fu J. Buyang Huanwu decoction ameliorates myocardial injury and attenuates platelet activation by regulating the PI3 kinase/Rap1/integrin α(IIb)β(3) pathway. Chin Med. 2024 Aug 19;19(1):109. doi: 10.1186/s13020-024-00976-0. PMID: 39160598; PMCID: PMC11331649. 【37】詹玲君,秦伟彬,何贵新,等.基于mitoKATP/PI3K/mTOR探讨芪参益气滴丸影响H9C2心肌细胞损伤后钙稳态及炎性环境的机制[J].时珍国医国药,2023,34(09):2087-2090.
1、国家自然科学基金(/upload/407803/20260605/20260605151828_6805.zip)
上一篇
下一篇
出版者信息








《广州医药》公众号
目录